
Maria Marvich
Examiner (ID: 13678, Phone: (571)272-0774 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1631, 1633, 1634, 1636 |
| Total Applications | 1493 |
| Issued Applications | 637 |
| Pending Applications | 231 |
| Abandoned Applications | 639 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18148348
[patent_doc_number] => 20230022205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/952565
[patent_app_country] => US
[patent_app_date] => 2022-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82404
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17952565
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/952565 | CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY | Sep 25, 2022 | Pending |
Array
(
[id] => 18178440
[patent_doc_number] => 20230039169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => Modified EC7 Cells Having Low Toxicity to Viral Production Payloads
[patent_app_type] => utility
[patent_app_number] => 17/932633
[patent_app_country] => US
[patent_app_date] => 2022-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932633
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/932633 | Modified EC7 Cells Having Low Toxicity to Viral Production Payloads | Sep 14, 2022 | Pending |
Array
(
[id] => 18612691
[patent_doc_number] => 20230279425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => POTENT AND BALANCED BIDIRECTIONAL PROMOTER
[patent_app_type] => utility
[patent_app_number] => 17/930158
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930158
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930158 | POTENT AND BALANCED BIDIRECTIONAL PROMOTER | Sep 6, 2022 | Pending |
Array
(
[id] => 18529983
[patent_doc_number] => 20230235051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => INHIBITORY CHIMERIC RECEPTOR ARCHITECTURES
[patent_app_type] => utility
[patent_app_number] => 17/820525
[patent_app_country] => US
[patent_app_date] => 2022-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50897
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820525 | INHIBITORY CHIMERIC RECEPTOR ARCHITECTURES | Aug 16, 2022 | Abandoned |
Array
(
[id] => 18093455
[patent_doc_number] => 20220411796
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/813843
[patent_app_country] => US
[patent_app_date] => 2022-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813843
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/813843 | COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION | Jul 19, 2022 | Pending |
Array
(
[id] => 18148533
[patent_doc_number] => 20230022390
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/812951
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23516
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812951
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/812951 | Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof | Jul 14, 2022 | Pending |
Array
(
[id] => 18264968
[patent_doc_number] => 20230086210
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => 4-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 17/811376
[patent_app_country] => US
[patent_app_date] => 2022-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33744
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811376
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811376 | 4-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES | Jul 7, 2022 | Pending |
Array
(
[id] => 18058370
[patent_doc_number] => 20220389456
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => MODIFIED SOLUBLE VEGF RECEPTOR-1 GENES AND VECTORS FOR GENE THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/856187
[patent_app_country] => US
[patent_app_date] => 2022-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7869
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17856187
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/856187 | MODIFIED SOLUBLE VEGF RECEPTOR-1 GENES AND VECTORS FOR GENE THERAPY | Jun 30, 2022 | Pending |
Array
(
[id] => 17982927
[patent_doc_number] => 20220348963
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => ADENOVIRAL- BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 17/855322
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5213
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17855322
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/855322 | ADENOVIRAL- BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS | Jun 29, 2022 | Pending |
Array
(
[id] => 18075943
[patent_doc_number] => 20220401555
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT
[patent_app_type] => utility
[patent_app_number] => 17/809680
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809680
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/809680 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT | Jun 28, 2022 | Pending |
Array
(
[id] => 18391701
[patent_doc_number] => 20230159919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => MODIFIED CRISPR RNA AND MODIFIED SINGLE CRISPR RNA AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/850456
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21485
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850456
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850456 | MODIFIED CRISPR RNA AND MODIFIED SINGLE CRISPR RNA AND USES THEREOF | Jun 26, 2022 | Pending |
Array
(
[id] => 18764255
[patent_doc_number] => 11814642
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Manufacturing and use of recombinant AAV vectors
[patent_app_type] => utility
[patent_app_number] => 17/848307
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 453
[patent_figures_cnt] => 29
[patent_no_of_words] => 40781
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848307
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/848307 | Manufacturing and use of recombinant AAV vectors | Jun 22, 2022 | Issued |
Array
(
[id] => 18484939
[patent_doc_number] => 20230212253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 17/843920
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 80676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 552
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843920 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | Jun 16, 2022 | Pending |
Array
(
[id] => 18077387
[patent_doc_number] => 20220402999
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 17/843916
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 80470
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 515
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843916
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843916 | Methods of obtaining tumor-specific T cell receptors | Jun 16, 2022 | Issued |
Array
(
[id] => 18077388
[patent_doc_number] => 20220403000
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 17/843917
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 80496
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 224
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843917
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843917 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | Jun 16, 2022 | Pending |
Array
(
[id] => 17911190
[patent_doc_number] => 20220313585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => Changing Eye Color by Gene Transduction
[patent_app_type] => utility
[patent_app_number] => 17/842658
[patent_app_country] => US
[patent_app_date] => 2022-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11662
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842658
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842658 | Changing eye color by gene transduction | Jun 15, 2022 | Issued |
Array
(
[id] => 18213104
[patent_doc_number] => 20230059368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => POLYNUCLEOTIDE EDITORS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/841029
[patent_app_country] => US
[patent_app_date] => 2022-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53342
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841029
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/841029 | POLYNUCLEOTIDE EDITORS AND METHODS OF USING THE SAME | Jun 14, 2022 | Abandoned |
Array
(
[id] => 17911826
[patent_doc_number] => 20220314221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/839667
[patent_app_country] => US
[patent_app_date] => 2022-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23436
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 177
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839667
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/839667 | MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION | Jun 13, 2022 | Pending |
Array
(
[id] => 18334825
[patent_doc_number] => 20230126773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => RECOMBINANT VIRUS REPLICON SYSTEMS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/806581
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15895
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806581
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/806581 | RECOMBINANT VIRUS REPLICON SYSTEMS AND USES THEREOF | Jun 12, 2022 | Pending |
Array
(
[id] => 19984306
[patent_doc_number] => 20250122528
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => LENTIVIRAL VECTOR
[patent_app_type] => utility
[patent_app_number] => 18/567499
[patent_app_country] => US
[patent_app_date] => 2022-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11889
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18567499
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/567499 | LENTIVIRAL VECTOR | Jun 7, 2022 | Pending |